Digirad Acquires Ultrascan
May 01 2007 - 4:01PM
Business Wire
Digirad Corporation (NASDAQ:DRAD), a leading provider of
cardiovascular imaging services and solid-state nuclear medicine
imaging products to physician offices, hospitals and imaging
centers, announced today that it has completed the acquisition of
privately held Ultrascan, Inc., a leading provider of mobile
ultrasound and nuclear medicine services primarily in Georgia, for
$7.25 million in cash and the assumption of $1.5 million of debt,
plus up to $3.85 million in cash and stock if Ultrascan achieves
certain EBITDA milestones over a four year period. Ultrascan
currently provides mobile ultrasound services to more than 100
clients through a 32-unit mobile fleet as well as fixed-site
nuclear imaging services at physician offices, clinics and
hospitals primarily in Georgia. "We are pleased to welcome the
Ultrascan team to the Digirad family," said Mark Casner, Chief
Executive Officer of Digirad. "This transaction diversifies
Digirad's services and expands our client base. It is a first step
in our strategy to create long-term growth by leveraging and
complementing Digirad's nuclear cardiology service capabilities
with other mobile imaging services. Ultrascan has differentiated
its services and added value to its well-established operating
platform by building a close working relationship with one of the
leading medical institutions in the Southeast. We believe this is
an important strategic asset that will enhance our competitiveness
in the Southeast market, and provides a model for our approach as
we expand in other areas." Mickey King, President and CEO of
Ultrascan, said, "We believe that the combination of Ultrascan and
Digirad creates growth opportunities in both ultrasound and nuclear
imaging, and will provide added value to our combined customer
base. Our experience in working with Digirad during the past year
has shown us that Ultrascan's mobile imaging delivery capability
and client base align well with Digirad's nuclear cardiology
services. We look forward to continuing to build our business in
combination with Digirad's strength and support." About Digirad
Digirad Corporation develops, manufactures and markets solid-state,
digital gamma cameras to hospitals, imaging centers and physician
offices. Digirad offers a comprehensive line of solid-state nuclear
gamma cameras that produce high-quality images for use in the
detection of many medical conditions, including cardiovascular
disease. Digirad's cameras are unique as their lightweight and
compact design allows them to fit easily into small office spaces.
Digirad's wholly owned subsidiary, Digirad Imaging Solutions (DIS),
offers a comprehensive mobile imaging leasing and services program
for physicians who wish to perform in-office nuclear cardiology and
ultrasound procedures without purchasing the equipment. For more
information, please visit www.digirad.com. Digirad�, Digirad
Imaging Solutions�, and Cardius� are registered trademarks of
Digirad Corporation. Forward-Looking Statements Digirad cautions
that statements included in this press release that are not a
description of historical facts are forward-looking statements. You
can identify these statements by the fact that they do not relate
strictly to historical or current facts and use words such as
"anticipate," "estimate," "expect," "project," "intend," "plan,"
"believe" and other words and terms of similar meaning in
connection with a discussion of future operating or financial
performance or events. Examples of such statements include the
statements regarding our expectations that Ultrascan acquisition
will be complementary to our DIS business and provides
opportunities for the diversification of our services, the
expansion of our client base and the creation of future growth; and
our belief that a relationship with a leading medical institution
will enhance our competitiveness and provide an expansion model.
The inclusion of these and other forward-looking statements should
not be regarded as a representation by Digirad that any of its
plans will be achieved. Actual results may differ materially from
those set forth in this press release due to the risks and
uncertainties inherent in Digirad's business including, without
limitation: the degree to which personnel changes and related
disruptions in our business activities may affect Digirad's
products, customers, work force, suppliers, and our overall
business prospects and operations; the degree to which Digirad's
camera systems and related services will be accepted by physicians
and hospitals some of whom may experience reliability issues or
technical problems; the ability of Digirad effectively to market,
sell and distribute its medical devices, and related services given
its limited capabilities in these areas; Digirad's ability to
manage risks relating to product liability, warranty claims,
recalls, property damage and personal injury with respect to its
imaging systems; and other risks detailed in Digirad's Securities
and Exchange Commission filings, including its Annual Report on
Form 10-K and other reports filed with the Securities and Exchange
Commission. Given these uncertainties, readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement and
Digirad undertakes no obligation to revise or update this press
release including the forward-looking statements contained herein
to reflect events or circumstances after the date hereof or to
update the reasons actual results could differ materially from
those anticipated in these forward-looking statements, even if new
information becomes available in the future.
Digirad (NASDAQ:DRAD)
Historical Stock Chart
From May 2024 to Jun 2024
Digirad (NASDAQ:DRAD)
Historical Stock Chart
From Jun 2023 to Jun 2024